Chronic Liver Disease and Cirrhosis

1. Overview

Cirrhosis represents the end-stage of chronic liver disease, characterised by diffuse hepatic fibrosis with replacement of normal liver architecture by structurally abnormal nodules. This irreversible process results from chronic hepatocellular injury from various aetiologies including viral hepatitis, alcohol, metabolic disorders, and autoimmune diseases. The condition progresses through a compensated phase, where patients may remain asymptomatic for years, to decompensation marked by ascites, variceal haemorrhage, hepatic encephalopathy, or jaundice.

The clinical significance of cirrhosis extends beyond liver dysfunction, as it is associated with systemic complications affecting multiple organ systems through mechanisms of portal hypertension, reduced synthetic function, and impaired immune responses. Cirrhosis is the 11th most common cause of death globally, accounting for over 1 million deaths annually. [1] Early identification and management of the underlying cause can prevent progression in compensated disease, whilst decompensated cirrhosis requires specialist management and consideration for liver transplantation.

The prognosis of cirrhosis depends critically on the stage of disease. Patients with compensated cirrhosis have a median survival exceeding 12 years, whereas those with decompensated disease have a median survival of approximately 2 years without transplantation. [2] Modern risk stratification using Child-Pugh and MELD scores guides clinical decision-making and transplant allocation.

2. Epidemiology

The global burden of cirrhosis continues to increase, reflecting the rising prevalence of risk factors including obesity, metabolic syndrome, and viral hepatitis. Understanding the epidemiology is essential for public health planning and individual risk assessment.

Geographic Variation

The aetiology of cirrhosis varies significantly by geography. In Western countries, alcohol-related liver disease and non-alcoholic fatty liver disease (NAFLD) predominate, accounting for 40-50% and 20-30% of cases respectively. [4] In contrast, hepatitis B virus (HBV) infection remains the leading cause in East Asia and sub-Saharan Africa, whilst hepatitis C virus (HCV) is prevalent in Egypt and parts of Eastern Europe. [4]

Demographic Risk Factors

• Age: Incidence increases with age, reflecting cumulative exposure to risk factors
• Sex: Males have higher rates of alcohol-related cirrhosis (2-3:1 ratio)
• Ethnicity: Hispanics have higher rates of NAFLD-related cirrhosis; HBV is more prevalent in Asian populations
• Socioeconomic status: Alcohol-related cirrhosis is more common in lower socioeconomic groups

Temporal Trends

The epidemiology of cirrhosis is evolving. Whilst the burden from viral hepatitis is declining due to effective antiviral therapies and vaccination programmes, NAFLD-related cirrhosis is projected to become the leading indication for liver transplantation in developed countries by 2030. [5] The obesity epidemic and metabolic syndrome are major drivers of this trend.

3. Aetiology and Pathophysiology

Major Aetiologies

Cirrhosis results from sustained hepatocellular injury from multiple potential causes:

Alcohol-Related Liver Disease (30-40% of cases)

• Dose-dependent relationship: risk increases with > 20-30g/day (women) or > 30-40g/day (men) [6]
• Not all heavy drinkers develop cirrhosis (only 10-20%), suggesting genetic susceptibility
• Progression: steatosis → alcoholic hepatitis → fibrosis → cirrhosis

Viral Hepatitis (25-35% of cases)

• Hepatitis C: 20-30% develop cirrhosis within 20-30 years of infection [7]
• Hepatitis B: 20-25% develop cirrhosis, higher with concurrent HBV/HDV or HBV/HIV [7]
• Direct antiviral agents for HCV can halt or reverse fibrosis in early stages

Non-Alcoholic Fatty Liver Disease/NASH (20-30% of cases)

• Associated with metabolic syndrome, diabetes, obesity
• NASH (inflammatory component) progresses to cirrhosis in 10-25% over 10-20 years [8]
• Emerging as leading cause in Western populations

Autoimmune Liver Diseases (5-10% of cases)

• Primary biliary cholangitis (PBC): progressive cholestatic disease
• Autoimmune hepatitis: hepatocellular inflammation responding to immunosuppression
• Primary sclerosing cholangitis (PSC): bile duct inflammation, association with IBD

Metabolic and Genetic Disorders (5-10% of cases)

• Haemochromatosis: iron overload with hepatic deposition
• Wilson disease: copper accumulation due to ATP7B mutations
• Alpha-1 antitrypsin deficiency: protein misfolding and hepatocyte injury

Other Causes (5-10% of cases)

• Biliary obstruction (secondary biliary cirrhosis)
• Cardiac cirrhosis (chronic right heart failure)
• Medications (methotrexate, amiodarone)
• Cryptogenic cirrhosis (unknown cause, likely unrecognised NASH)

Molecular Pathophysiology of Fibrosis

The development of hepatic fibrosis is a complex process involving multiple cell types and molecular pathways. Understanding these mechanisms is crucial for postgraduate examinations and emerging therapeutic targets.

Hepatic Stellate Cell Activation (Central Mechanism)

Hepatic stellate cells (HSCs) reside in the space of Disse in their quiescent state, storing vitamin A. Following liver injury, HSCs undergo activation and transdifferentiation into myofibroblasts, becoming the primary source of extracellular matrix (ECM) deposition. [9]

Key steps in HSC activation:

1. Initiation: Paracrine stimuli from damaged hepatocytes and Kupffer cells (TGF-β, PDGF, reactive oxygen species)
2. Perpetuation: Autocrine signalling maintains activated phenotype
3. ECM Production: Synthesis of collagen I, III, and IV; fibronectin; and other matrix proteins
4. Matrix Remodelling: Secretion of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs)

Molecular Signalling Pathways

• TGF-β/Smad Pathway: TGF-β1 is the most potent profibrogenic cytokine, signalling through Smad2/3 phosphorylation and nuclear translocation to drive collagen gene transcription [9]
• PDGF Signalling: Platelet-derived growth factor promotes HSC proliferation and chemotaxis via PDGF receptor activation
• Hedgehog Pathway: Upregulated in cirrhosis, promotes HSC activation and liver progenitor cell expansion
• Wnt/β-Catenin: Regulates HSC fate and fibrogenic responses

Inflammatory Cell Recruitment

• Kupffer cells (hepatic macrophages) release inflammatory cytokines (TNF-α, IL-1, IL-6) that promote HSC activation
• Neutrophil and lymphocyte infiltration amplifies tissue injury
• M1 macrophages drive fibrogenesis whilst M2 macrophages may promote resolution

Oxidative Stress and Lipid Peroxidation

Reactive oxygen species (ROS) generated from multiple sources (mitochondria, cytochrome P450 2E1, NADPH oxidase) cause:

• Direct hepatocyte damage
• HSC activation via oxidative stress response pathways
• Lipid peroxidation products (malondialdehyde, 4-hydroxynonenal) that stimulate fibrogenesis

Sinusoidal Remodelling and Angiogenesis

Progressive fibrosis leads to:

• Loss of sinusoidal endothelial fenestrations (capillarisation)
• Increased vascular resistance contributing to portal hypertension
• Pathological angiogenesis driven by VEGF and angiopoietins

Progression from Fibrosis to Cirrhosis

Fibrosis progresses through four histological stages (F0-F4 on METAVIR or Ishak scoring systems). Cirrhosis (F4) is defined by complete bridging fibrosis with nodular regeneration and architectural distortion. The progression rate varies by aetiology:

• HCV: 0.1-0.3 units per year on average [10]
• Alcohol: highly variable, depends on continued consumption
• NASH: slower progression, 0.03-0.07 units per year [8]

Factors Accelerating Fibrosis Progression:

• Continued alcohol consumption
• Concurrent viral hepatitis infections (HBV/HCV, HBV/HDV, HIV co-infection)
• Metabolic syndrome and insulin resistance
• Male sex and older age at infection
• Immunosuppression

Pathophysiology of Portal Hypertension

Portal hypertension, defined as portal pressure gradient > 5mmHg (clinically significant when > 10mmHg), results from increased intrahepatic vascular resistance and splanchnic vasodilation. [11]

Increased Intrahepatic Resistance:

• Structural component: fibrosis, nodular regeneration, vascular remodelling
• Dynamic component: increased HSC and myofibroblast contractility (modulated by endothelin-1, norepinephrine, angiotensin II)
• Endothelial dysfunction with reduced nitric oxide production

Splanchnic Vasodilation:

• Mediated by nitric oxide, carbon monoxide, endocannabinoids
• Leads to increased portal inflow despite elevated resistance
• Hyperdynamic circulation with increased cardiac output

Consequences:

• Portosystemic collateral formation (varices, caput medusae, rectal varices)
• Splenomegaly and hypersplenism
• Ascites formation (increased hydrostatic pressure + hypoalbuminaemia)

4. Clinical Presentation

The clinical presentation of cirrhosis varies markedly between compensated and decompensated disease. Many patients with compensated cirrhosis are asymptomatic, and the diagnosis may be incidental following abnormal liver biochemistry or imaging.

Compensated Cirrhosis

Symptoms (Often Minimal or Absent)

• Fatigue and reduced exercise tolerance (most common symptom, present in 40-60%) [12]
• Pruritus (particularly in cholestatic liver disease)
• Right upper quadrant discomfort
• Anorexia and weight loss
• Decreased libido and erectile dysfunction

Signs

• Stigmata of chronic liver disease (see below)
• Hepatomegaly (early) or small, nodular liver (advanced)
• Splenomegaly (due to portal hypertension)
• Spider naevi (> 5 is significant, found in superior vena cava distribution)
• Palmar erythema
• Digital clubbing
• Dupuytren contracture (especially alcohol-related)
• Gynaecomastia and testicular atrophy (hyperestrogenism)

Decompensated Cirrhosis

Decompensation is defined by development of ascites, variceal haemorrhage, hepatic encephalopathy, or jaundice. Median time to first decompensation in compensated cirrhosis is 3-5 years. [2]

Ascites (Most Common First Decompensation Event, 40-50%)

Symptoms:

• Abdominal distension and discomfort
• Early satiety
• Dyspnoea (if tense ascites or hepatic hydrothorax)
• Ankle and leg oedema

Signs:

• Bulging flanks
• Shifting dullness (detects > 1500mL fluid)
• Fluid thrill (requires significant ascites)
• Umbilical eversion or herniation

Variceal Haemorrhage (30-35% First Decompensation)

Presentation:

• Haematemesis (coffee-ground or fresh blood)
• Melaena
• Haematochezia (if massive bleed)
• Signs of hypovolaemic shock (tachycardia, hypotension)
• Precipitates hepatic encephalopathy

Hepatic Encephalopathy (20-25% First Decompensation)

West Haven Criteria:

• Grade 1: Altered mood, sleep disturbance, mild confusion
• Grade 2: Lethargy, disorientation, asterixis
• Grade 3: Somnolence, confusion, incoherent speech
• Grade 4: Coma

Jaundice

• Yellow discolouration of skin and sclera
• Dark urine (conjugated hyperbilirubinaemia)
• Indicates severe hepatic dysfunction or acute decompensation

Physical Examination Findings by System

Red Flag Features

• Acute decompensation: Requires urgent hospital admission
• Variceal haemorrhage: Mortality 15-20% at 6 weeks despite treatment [13]
• Spontaneous bacterial peritonitis: Fever, abdominal pain in patient with ascites
• Hepatorenal syndrome: Rising creatinine in absence of other renal pathology
• Hepatocellular carcinoma: New liver lesion, rising AFP, abdominal pain

5. Differential Diagnosis

The presentation of cirrhosis, particularly when decompensated, must be distinguished from other conditions:

Ascites Differentials (Once Ascites Demonstrated):

Serum-Ascites Albumin Gradient (SAAG) is key:

• SAAG ≥11 g/L (Portal hypertension): Cirrhosis, cardiac ascites, Budd-Chiari, portal vein thrombosis
• SAAG less than 11 g/L (Non-portal hypertension): Peritoneal carcinomatosis, tuberculous peritonitis, pancreatitis, nephrotic syndrome

6. Investigations

A systematic approach to investigation establishes the diagnosis, determines aetiology, assesses severity, and screens for complications.

First-Line Investigations

Blood Tests

Liver Biochemistry:

• ALT/AST: May be normal in compensated cirrhosis; AST:ALT ratio > 2 suggests alcohol-related disease [14]
• ALP/GGT: Elevated in cholestatic liver disease (PBC, PSC)
• Bilirubin: Rises with advancing disease; conjugated hyperbilirubinaemia
• Albumin: Reduced (less than 35 g/L) indicates impaired synthetic function
• INR/PT: Prolonged INR indicates coagulopathy, used in Child-Pugh and MELD scores

Haematology:

• Full blood count: Thrombocytopaenia (less than 150 × 10⁹/L) due to hypersplenism and reduced thrombopoietin
• Macrocytosis (alcohol, folate deficiency)
• Anaemia (multifactorial: chronic disease, GI bleeding, nutritional deficiency)

Renal Function:

• Urea and creatinine: Essential for detecting hepatorenal syndrome
• Electrolytes: Hyponatraemia common in decompensated cirrhosis (dilutional)

Aetiological Screen

All patients require investigation for reversible causes:

Imaging

Ultrasound (First-Line):

• Liver echotexture: Coarse, nodular in cirrhosis
• Liver size: Often reduced with irregular margins
• Portal vein: Diameter, flow direction (hepatofugal flow indicates advanced portal hypertension)
• Splenomegaly, ascites
• Hepatocellular carcinoma surveillance (6-monthly)

Transient Elastography (FibroScan):

• Non-invasive assessment of liver stiffness (correlates with fibrosis stage)
• Liver stiffness > 12.5 kPa suggests cirrhosis (sensitivity 87%, specificity 91%) [15]
• Useful for monitoring disease progression
• Limitations: Obesity, ascites, acute hepatitis

Second-Line Investigations

Endoscopy

Oesophagogastroduodenoscopy (OGD):

• Screening for varices in all newly diagnosed cirrhosis (Child-Pugh B/C or platelet less than 150, splenomegaly)
• Grading: Small (less than 5mm) vs large (> 5mm) varices
• Presence of red spots indicates high bleeding risk
• Repeat every 1-3 years depending on initial findings and severity [16]

Advanced Imaging

CT Abdomen with Contrast:

• Detailed hepatic parenchymal assessment
• Identify mass lesions (HCC surveillance)
• Portal vein patency and portosystemic collaterals
• Assess for hepatic artery and venous anatomy pre-transplant

MRI Liver with Hepatocyte-Specific Contrast:

• Superior characterisation of liver lesions
• Differentiate dysplastic nodules from HCC
• MR elastography for fibrosis quantification

Ascitic Fluid Analysis

Essential in all patients with new ascites or clinical deterioration:

Liver Biopsy

Indications:

• Uncertain diagnosis despite non-invasive tests
• Assessment of disease activity and grade (particularly autoimmune hepatitis)
• Determining contribution of multiple aetiologies

Route:

• Percutaneous (contraindicated if INR > 1.4, platelets less than 60 × 10⁹/L, ascites)
• Transjugular (preferred if coagulopathy or ascites; allows hepatic venous pressure measurement)

Histological Features:

• Fibrosis with bridging (Ishak stage 5-6 or METAVIR F4)
• Nodular regeneration
• Loss of normal architecture
• Specific features (e.g., steatohepatitis, interface hepatitis, copper deposition)

Severity Assessment Scores

Child-Pugh Score

Five parameters, each scored 1-3 points:

Classification:

• Class A: 5-6 points (well-compensated, 1-year survival ~100%)
• Class B: 7-9 points (significant functional impairment, 1-year survival ~80%)
• Class C: 10-15 points (decompensated, 1-year survival ~45%)

MELD Score (Model for End-Stage Liver Disease)

Calculated using bilirubin, creatinine, and INR:

MELD = 3.78×ln[bilirubin (mg/dL)] + 11.2×ln(INR) + 9.57×ln[creatinine (mg/dL)] + 6.43

• Used for liver transplant prioritisation
• Range: 6-40 (capped at 40)
• 3-month mortality correlation: MELD 10 (1.9%), MELD 20 (6.0%), MELD 30 (19.6%), MELD 40 (71.3%) [17]
• MELD-Na incorporates serum sodium for improved prediction in patients with hyponatraemia

7. Management

Management of cirrhosis aims to treat the underlying cause, prevent disease progression, manage complications, and assess suitability for liver transplantation.

General Principles

Treat Underlying Cause

Lifestyle Modifications

• Abstinence from alcohol (all aetiologies)
• Maintain adequate nutrition (protein 1.2-1.5 g/kg/day to prevent sarcopaenia) [18]
• Avoid hepatotoxic drugs (NSAIDs, paracetamol > 2g/day)
• Vaccinations: Hepatitis A, hepatitis B, pneumococcus, influenza, COVID-19
• Avoid raw shellfish (risk of Vibrio vulnificus infection)

Management of Complications

Ascites Management

Classification:

• Grade 1: Mild, detectable only on ultrasound
• Grade 2: Moderate, symmetrical distension
• Grade 3: Severe, tense ascites

First-Line Treatment (Grade 2-3 Ascites)

Dietary Sodium Restriction:

• Limit to less than 90 mmol/day (5-6g salt)
• More effective than fluid restriction alone

Diuretic Therapy:

• Spironolactone 100mg OD (start dose 50-100mg, increase by 100mg every 3-7 days, max 400mg)
• Add furosemide 40mg OD if inadequate response (maintain 100:40 ratio of spironolactone:furosemide)
• Monitor U&Es, especially potassium and creatinine
• Target weight loss 0.5kg/day (without peripheral oedema) or 1kg/day (with peripheral oedema)

Refractory Ascites (Defined as Failure to Mobilise Ascites or Early Recurrence)

Large Volume Paracentesis (LVP):

• Drainage of ≥5L ascites
• Albumin replacement: 8g per litre removed (if > 5L drained) to prevent post-paracentesis circulatory dysfunction [19]
• Can be repeated as required

Transjugular Intrahepatic Portosystemic Shunt (TIPS):

• Creates shunt between portal and hepatic veins, reducing portal pressure
• Indications: Refractory ascites unresponsive to medical therapy, recurrent variceal bleeding
• Reduces ascites recurrence (58% vs 26% with paracentesis) [20]
• Contraindications: Hepatic encephalopathy, right heart failure, polycystic liver, severe hepatic dysfunction (Child-Pugh > 12)
• Complications: HE (30-40%), TIPS stenosis/occlusion

Liver Transplantation:

• Definitive treatment for refractory ascites
• Refer early if meeting criteria (MELD ≥15 or refractory complications)

Spontaneous Bacterial Peritonitis (SBP)

Diagnosis:

• Ascitic neutrophil count > 250 cells/µL
• Symptoms: Fever, abdominal pain, altered mental status (but 10-30% asymptomatic)
• Ascitic fluid culture positive in only 40% (send 10mL into blood culture bottles)

Treatment:

• Empirical antibiotic: Cefotaxime 2g IV TDS or ceftriaxone 2g IV OD for 5 days
• IV albumin 1.5g/kg day 1, then 1g/kg day 3 (reduces renal impairment and mortality) [21]
• Response expected within 48 hours (repeat paracentesis if no improvement)

Prophylaxis:

• Primary prophylaxis: Ascitic protein less than 15 g/L with advanced cirrhosis (Child-Pugh ≥9) or renal impairment: norfloxacin 400mg OD or ciprofloxacin 500mg OD
• Secondary prophylaxis: Following SBP episode: norfloxacin 400mg OD indefinitely or until transplant

Hepatic Encephalopathy (HE)

Pathophysiology:

• Ammonia accumulation (from gut bacterial metabolism and reduced hepatic clearance)
• Crosses blood-brain barrier → astrocyte swelling and neurotransmitter imbalance
• Precipitants: Infection, GI bleeding, constipation, dehydration, sedatives, dietary protein load, electrolyte disturbance

Grading (West Haven Criteria):

• Grade 0 (Minimal HE): Subclinical, detected on psychometric testing
• Grade 1: Altered mood/behaviour, sleep disturbance, mild confusion, asterixis
• Grade 2: Lethargy, disorientation, inappropriate behaviour, asterixis
• Grade 3: Somnolence, severe confusion, incoherent speech
• Grade 4: Coma, unresponsive to painful stimuli

Treatment:

Identify and Treat Precipitants:

• Infection screen (septic screen, diagnostic paracentesis)
• Review medications (stop sedatives, opioids)
• Ensure bowel regularity

Ammonia-Lowering Therapy:

• Lactulose 15-30mL BD-TDS, titrate to 2-3 soft stools per day (reduces colonic pH, traps ammonia as NH4+, and acts as osmotic laxative)
• Rifaximin 550mg BD (non-absorbable antibiotic, reduces ammonia-producing gut bacteria; combined with lactulose reduces HE recurrence by 50%) [22]

Nutritional Support:

• Adequate protein intake (1.2-1.5 g/kg/day); protein restriction is NOT recommended
• Branched-chain amino acids may have benefit but evidence limited

Severe HE (Grade 3-4):

• ITU admission, airway protection if GCS ≤8
• Lactulose via NG tube
• Exclude other causes (intracranial bleed, stroke, metabolic)

Prophylaxis:

• Rifaximin ± lactulose for patients with previous overt HE episodes

Variceal Bleeding

Prevention (Primary Prophylaxis)

Screening:

• OGD at diagnosis for all cirrhotic patients (Child-Pugh B/C, platelet less than 150 × 10⁹/L, or splenomegaly)
• Repeat endoscopy: Every 2-3 years (no varices), every 1-2 years (small varices)

Prophylactic Treatment:

• No varices: No treatment required
• Small varices without red signs: Non-selective beta-blocker (NSBB) if high-risk features (Child-Pugh B/C)
• Large varices or small with red signs:
  • "Preferred: Non-selective beta-blocker (propranolol 20-40mg BD or carvedilol 6.25-12.5mg OD), titrate to heart rate 55-60 bpm or 25% reduction from baseline"
  • "Alternative: Endoscopic variceal band ligation (EVL) if beta-blockers contraindicated or not tolerated"
  • Beta-blockers reduce bleeding risk by ~40-50% and mortality [23]

Acute Variceal Bleeding Management

Immediate Resuscitation:

• ABC approach, large-bore IV access, crossmatch 4-6 units
• Haemodynamic resuscitation: Target Hb 70-80 g/L (restrictive transfusion strategy reduces rebleeding)
• Correct coagulopathy judiciously (avoid over-transfusion of FFP/platelets as increases portal pressure)
• Antibiotics: Ceftriaxone 1g IV OD (reduces infection, mortality, and rebleeding) [24]
• Terlipressin 2mg IV bolus then 1-2mg every 4-6 hours (splanchnic vasoconstrictor, reduces rebleeding)

Endoscopic Therapy:

• Urgent OGD (within 12 hours of presentation)
• Oesophageal varices: Endoscopic variceal band ligation (EVL) - first-line
• Gastric varices: Cyanoacrylate injection
• Success rate of EVL: 80-90%

Rescue Therapy (if Uncontrolled Bleeding):

• Sengstaken-Blakemore tube (balloon tamponade) - temporary measure (max 24 hours)
• Emergency TIPS within 72 hours (Child-Pugh B/C with active bleeding or early rebleeding)
• Salvage TIPS reduces mortality in high-risk patients (Child-Pugh B with active bleeding or Child-Pugh C less than 14) [25]

Secondary Prophylaxis:

• Combination of NSBB (propranolol or carvedilol) + EVL (repeat sessions every 2-4 weeks until variceal eradication)
• TIPS if rebleeding despite above measures

Hepatorenal Syndrome (HRS)

Classification:

HRS-AKI (formerly Type 1):

• Rapid increase in creatinine (≥26.5 µmol/L within 48 hours or ≥50% from baseline)
• Median survival less than 2 weeks without treatment

HRS-CKD (formerly Type 2):

• Progressive but slower decline in renal function
• Associated with refractory ascites

Diagnostic Criteria (ICA-AKI 2019):

• Cirrhosis with ascites
• AKI according to ICA-AKI criteria
• No response to diuretic withdrawal and volume expansion with albumin (1 g/kg for 2 days, max 100g/day)
• No shock, nephrotoxic drugs, or parenchymal renal disease

Treatment:

HRS-AKI:

• Vasoconstrictor therapy: Terlipressin 0.5-2mg IV every 4-6 hours (increases mean arterial pressure and renal perfusion)
• Albumin: 20-40g IV daily
• Treatment duration: Until creatinine less than 133 µmol/L or max 14 days
• Response rate: 40-50% with terlipressin + albumin
• Alternatives: Noradrenaline (in ICU setting), midodrine + octreotide (less effective)

Renal Replacement Therapy:

• Bridge to liver transplantation in selected cases
• Prognosis poor without transplantation

Definitive Treatment:

• Liver transplantation (simultaneous liver-kidney transplant if sustained renal dysfunction > 4 weeks)

Hepatocellular Carcinoma (HCC) Surveillance

Screening Protocol:

Who to Screen:

• All cirrhotic patients regardless of aetiology
• Selected non-cirrhotic patients: HBV carriers, advanced fibrosis (F3)

Surveillance Interval:

• 6-monthly ultrasound ± AFP
• 6-month interval more cost-effective than 3-month (detects early HCC with acceptable sensitivity) [26]

AFP Role:

• Adjunct to ultrasound (increases sensitivity but reduces specificity)
• AFP > 20 ng/mL warrants further imaging even if ultrasound negative

Management of Detected Lesions:

Lesion less than 1 cm:

• Repeat ultrasound at 3 months
• If growing or characteristics change, proceed to CT/MRI

Lesion ≥1 cm:

• Multiphase CT or MRI (arterial phase enhancement with washout on portal venous/delayed phase is diagnostic)
• Biopsy rarely needed (risk of seeding)

Treatment Options (by Barcelona Clinic Liver Cancer Staging):

• Very early/early HCC (BCLC 0/A): Resection, ablation (RFA/microwave), or transplantation
• Intermediate (BCLC B): Transarterial chemoembolisation (TACE)
• Advanced (BCLC C): Systemic therapy (sorafenib, lenvatinib)
• Terminal (BCLC D): Best supportive care

Liver Transplantation

Indications:

Transplant referral should occur when:

• MELD score ≥15
• First episode of decompensation (ascites, variceal bleeding, HE, jaundice)
• Hepatocellular carcinoma within Milan criteria (single lesion ≤5cm or ≤3 lesions each ≤3cm)
• Specific complications: Refractory ascites, recurrent HE, hepatopulmonary syndrome

Absolute Contraindications:

• Extrahepatic malignancy
• Severe cardiopulmonary disease
• Active sepsis
• Anatomical abnormalities precluding transplant
• Active alcohol or substance abuse (less than 6 months abstinence for alcohol)

Relative Contraindications:

• Age > 70 years
• HIV infection (controlled viral load acceptable in many centres)
• Portal vein thrombosis (may require thrombectomy)
• Prior extensive abdominal surgery

Allocation:

• MELD score-based prioritisation (higher score = higher mortality risk = higher priority)
• Exception points for HCC within Milan criteria

Post-Transplant:

• 1-year survival: 85-90%
• 5-year survival: 70-75%
• Lifelong immunosuppression (tacrolimus, mycophenolate mofetil ± steroids)

8. Complications

Beyond the major decompensating events discussed above, cirrhosis leads to numerous complications affecting multiple organ systems.

9. Prognosis

Natural History

• Compensated cirrhosis: Median survival > 12 years; annual risk of decompensation 5-7% [2]
• First decompensation: Median survival drops to ~2 years
• Child-Pugh A: 1-year survival 100%, 2-year survival 85%
• Child-Pugh B: 1-year survival 80%, 2-year survival 60%
• Child-Pugh C: 1-year survival 45%, 2-year survival 35%

Prognostic Factors

Favourable:

• Abstinence from alcohol
• Viral suppression (HBV/HCV)
• Early stage (compensated)
• Absence of portal hypertension
• Good nutritional status

Adverse:

• Continued alcohol consumption
• Development of HCC
• Renal impairment
• Hyponatraemia (dilutional)
• Recurrent infections
• Sarcopaenia

Baveno Criteria (Compensated Cirrhosis)

Used to stratify risk and avoid endoscopy in low-risk patients:

• Liver stiffness less than 20 kPa AND platelet count > 150 × 10⁹/L → Low risk of varices requiring treatment (can defer screening OGD)

10. Prevention and Screening

Primary Prevention:

• Alcohol moderation and public health measures
• HBV vaccination (universal childhood vaccination in endemic areas)
• Screening blood products for HCV
• Weight management and prevention of metabolic syndrome
• Avoid hepatotoxic medications

Screening for Cirrhosis:

Not routine population screening, but targeted screening in high-risk groups:

• Known chronic liver disease (annual FibroScan/imaging)
• HBV/HCV carriers
• Alcohol use disorder
• Metabolic syndrome with elevated ALT

11. Key Guidelines

• EASL Clinical Practice Guidelines: Management of patients with decompensated cirrhosis (2018)
• AASLD/EASL: Management of hepatic encephalopathy (2014, updated 2022)
• Baveno VII Consensus: Portal hypertension and variceal bleeding (2022)
• NICE NG50: Cirrhosis in over 16s - assessment and management (2016)
• AASLD: HCC surveillance guidelines (2018)

---

12. Examination Focus

Common Exam Questions

1. "Describe your approach to investigating a patient with suspected cirrhosis"
2. "How would you manage a patient with newly diagnosed oesophageal varices?"
3. "What is your approach to a cirrhotic patient with ascites and abdominal pain?"
4. "Discuss the indications for liver transplantation in cirrhosis"
5. "Explain the pathophysiology of hepatic encephalopathy and its management"
6. "What scoring systems are used to assess severity of cirrhosis?"

Viva Points

Opening Statement:

"Cirrhosis is the end-stage of chronic liver disease characterised by diffuse hepatic fibrosis with nodular regeneration and architectural distortion. The major causes include alcohol, viral hepatitis (HBV and HCV), NAFLD, and autoimmune liver diseases. The key distinction is between compensated cirrhosis, which may be asymptomatic, and decompensated cirrhosis presenting with ascites, variceal bleeding, hepatic encephalopathy, or jaundice."

Key Points for Viva:

1. Child-Pugh Score: 5 parameters (bilirubin, albumin, INR, ascites, encephalopathy), each scored 1-3. Class A (5-6 points), B (7-9), C (10-15). Prognostic tool.

2. MELD Score: Calculated from bilirubin, creatinine, INR. Used for transplant prioritisation. Predicts 3-month mortality.

3. Decompensation Events: Four main events - ascites (most common first), variceal bleeding, HE, jaundice. Median survival drops from > 12 years to ~2 years after first decompensation.

4. Variceal Prophylaxis: Primary prophylaxis with non-selective beta-blockers (propranolol, carvedilol) or EVL for large varices. Reduces bleeding risk by 40-50%.

5. SBP Diagnosis: Ascitic neutrophils > 250 cells/µL. Treat with cefotaxime + albumin. Prophylaxis with norfloxacin if low ascitic protein or previous SBP.

6. HCC Surveillance: 6-monthly ultrasound ± AFP in all cirrhotic patients. Lifetime risk 1-3% per year in cirrhosis.

7. TIPS Indications: Refractory ascites, recurrent variceal bleeding despite medical/endoscopic therapy. Risk of HE in 30-40%.

8. Transplant Referral: MELD ≥15, first decompensation event, refractory complications, HCC within Milan criteria.

Common Mistakes

• Failing to screen for HCC with 6-monthly ultrasound
• Inadequate alcohol history or not assessing abstinence
• Not recognising spontaneous bacterial peritonitis (fever + ascites = diagnostic tap)
• Missing indication for primary prophylaxis of varices
• Protein restriction in hepatic encephalopathy (outdated - maintain adequate protein)
• Over-aggressive fluid resuscitation in variceal bleeding (increases portal pressure)
• Not giving terlipressin and antibiotics in acute variceal bleed
• Forgetting albumin replacement after large-volume paracentesis (> 5L)

Model Answer Example

Q: How would you manage refractory ascites in a cirrhotic patient?

A: "Refractory ascites is defined as ascites that cannot be mobilised or recurs rapidly despite maximal diuretic therapy (spironolactone 400mg and furosemide 160mg daily) and sodium restriction. My approach would be:

First, I would confirm true refractoriness by ensuring compliance with sodium restriction and diuretics, and excluding other causes of fluid retention like cardiac or renal disease.

For management, the options are:

1. Serial large-volume paracentesis: Drainage of ≥5 litres with albumin replacement at 8g per litre drained. This is safe and can be repeated as needed. I would monitor for post-paracentesis circulatory dysfunction.

2. TIPS: This creates a portosystemic shunt reducing portal pressure. It's indicated if frequent paracentesis is required. TIPS reduces ascites recurrence significantly - around 58% compared to 26% with paracentesis alone. However, it carries a 30-40% risk of hepatic encephalopathy and is contraindicated if baseline encephalopathy or severe hepatic dysfunction (Child-Pugh > 12).

3. Liver transplantation: Refractory ascites is a clear indication for transplant referral as it indicates MELD ≥15 typically. This is the definitive treatment.

I would also ensure the patient is on SBP prophylaxis with norfloxacin if ascitic protein is low (less than 15 g/L), and assess for other complications like HCC and varices."

---

References

1. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245-266. doi:10.1016/S2468-1253(19)30349-8

2. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-231. doi:10.1016/j.jhep.2005.10.013

3. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171. doi:10.1016/j.jhep.2018.09.014

4. Sepanlou SG, Safiri S, Bisignano C, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017. Lancet Gastroenterol Hepatol. 2020;5(3):245-266. doi:10.1016/S2468-1253(19)30349-8

5. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466

6. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437-445. doi:10.1111/j.1465-3362.2009.00153.x

7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-2593. doi:10.1001/jama.2012.144878

8. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-654. doi:10.1016/j.cgh.2014.04.014

9. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125-172. doi:10.1152/physrev.00013.2007

10. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-431. doi:10.1002/hep.22375

11. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-335. doi:10.1002/hep.28906

12. Swain MG. Fatigue in chronic disease. Clin Sci (Lond). 2000;99(1):1-8. doi:10.1042/cs0990001

13. Reverter E, Tandon P, Augustin S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146(2):412-419. doi:10.1053/j.gastro.2013.10.018

14. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004;39(4):336-339. doi:10.1093/alcalc/agh074

15. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847. doi:10.1016/j.jhep.2008.02.008

16. de Franchis R; Baveno VII Faculty. Expanding consensus in portal hypertension: Report of the Baveno VII Consensus Workshop. J Hepatol. 2022;76(4):959-974. doi:10.1016/j.jhep.2021.12.022

17. Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805. doi:10.1002/hep.21563

18. Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38(2):485-521. doi:10.1016/j.clnu.2018.12.022

19. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181. doi:10.1002/hep.24786

20. Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157-163. doi:10.1053/j.gastro.2016.09.016

21. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409. doi:10.1056/NEJM199908053410603

22. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081. doi:10.1056/NEJMoa0907893

23. Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64(11):1680-1704. doi:10.1136/gutjnl-2015-309262

24. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(9):CD002907. doi:10.1002/14651858.CD002907.pub2

25. Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2370-2379. doi:10.1056/NEJMoa0910102

26. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi:10.1371/journal.pmed.1001624

---

Last Reviewed: 2026-01-05 | MedVellum Editorial Team